Results 71 to 80 of about 65,667 (194)

Ajugol Improves Liver Fibrosis by Modulating Bile Acid and Arachidonic Acid Metabolism in Mice

open access: yesPhytotherapy Research, EarlyView.
Ajujol ameliorates hepatic fibrosis by regulating bile acid metabolism and suppressing inflammatory responses. ABSTRACT Ajugol (AJ), the primary component extracted from the root of Rehmannia glutinosa, exhibits protective effects against metabolic dysregulation and chronic inflammation.
Xia Wei   +9 more
wiley   +1 more source

Post-liver transplant intrahepatic cholestasis : etiology, clinical presentation, therapy [PDF]

open access: yes, 2017
Post-liver transplant intrahepatic cholestasis is consequent to the impairment of bile flow or formation. It may develop in the early (within 6 months) or in the late (more than 6 months) post-liver transplant period and different causes may be ...
V.M. Mazzaferro   +8 more
core   +2 more sources

Adverse Pregnancy Outcomes and Prognostic Factors in Hepatitis B Virus Patients with Intrahepatic Cholestasis During Pregnancy

open access: yesClinical and Experimental Obstetrics & Gynecology
Background: We conducted this study to investigate adverse pregnancy outcomes of hepatitis B virus infection coexistng with intrahepatic cholestasis in pregnant women, along with identifying associated risk factors.
Chong Zhang   +3 more
doaj   +1 more source

Benign recurrent intrahepatic cholestasis

open access: yes, 2005
Benign recurrent intrahepatic cholestasis (BRIC) is a rare cause of cholestasis in children. The disease may start in infancy or early childhood.
Bhatia, Baldev D   +5 more
core   +1 more source

Integrative proteomic profiling of extracellular vesicle‐enriched preparations with machine learning identifies disease activity‐associated signatures linked to adverse pregnancy outcomes in systemic lupus erythematosus

open access: yesVIEW, EarlyView.
Integrating cross‐cohort extracellular vesicle proteomics with machine learning identifies a simplified protein signature (AGT, FETUB, SPP2, and FCN3) for adverse pregnancy outcome risk stratification in systemic lupus erythematosus, enabling precise disease‐activity discrimination beyond routine clinical assessment.
Weiwei Shi   +5 more
wiley   +1 more source

Immune‐related hepatobiliary adverse events associated with mogamulizumab: A case series and literature review

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Mogamulizumab is a monoclonal antibody targeting CC‐chemokine receptor‐4 that is approved as a second‐line therapy for mycosis fungoides and Sézary syndrome. The most common adverse events include infusion‐related reactions and mogamulizumab‐associated rash.
Inga Hansen‐Abeck   +6 more
wiley   +1 more source

A novel case report of benign recurrent intrahepatic cholestasis-associated USP53 genetic mutation in a Pakistani girl

open access: yesSAGE Open Medical Case Reports
Benign recurrent intrahepatic cholestasis is an autosomal recessive disorder presenting with intermittent episodes of cholestatic jaundice. The initial episode of benign recurrent intrahepatic cholestasis tends to occur within the first two decades of a ...
Tafiya Erum Kamran   +7 more
doaj   +1 more source

Indoleamine 2,3‐Dioxygenase 1 as an Adjunctive Histopathological Marker of Cholangitis Activity in Primary Biliary Cholangitis

open access: yesHepatology Research, EarlyView.
IDO‐1 immunostaining identifies primary biliary cholangitis even in morphologically subtle bile duct lesions. IDO‐1 expression reflects cholangitis activity and is suppressed by ursodeoxycholic acid treatment, indicating its value as a dynamic diagnostic adjunct rather than a static marker of chronic damage.
Kaori Yoshimura   +10 more
wiley   +1 more source

Transcriptional regulation of hepatobiliary transport systems in health and disease: Implications for a rationale approach to the treatment of intrahepatic cholestasis

open access: yesAnnals of Hepatology, 2005
Hepatobiliary transport systems mediate hepatic uptake and biliary excretion of bile acids, bilirubin and other biliary constituents. Hereditary or acquired defects of these transporters may cause or maintain cholestasis and jaundice under various ...
Martin Wagner, Michael Trauner
doaj   +1 more source

Cisterna Chyli Dilation Is a Risk Factor for Liver Nodules and Hepatocellular Carcinoma in Fontan‐Associated Liver Disease: Pathophysiological Role of Lymphatic Dysfunction

open access: yesHepatology Research, EarlyView.
ABSTRACT Aim In Fontan‐associated liver disease (FALD), chronic congestion often confounds conventional fibrosis markers, complicating surveillance for hepatocellular carcinoma (HCC). Although lymphatic dysfunction is fundamental to Fontan physiology, its contribution to hepatocarcinogenesis remains unclear.
Koji Imoto   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy